GMP issues, death reports hit Chinese hepatitis B vaccines
This article was originally published in Scrip
Executive Summary
China is facing a serious shortage of recombinant hepatitis B vaccines because three major domestic manufacturers – Dalian-based Hissen, Shenzhen-based Bio Kangtai and Tiantan Biological Products of Beijing– officially halted production of their products on 1 January.